DETECTION OF VARIOUS BETA-LACTAMASES IN MDR ISOLATES OF FAMILY ENTEROBACTERIACEAE

Rama Sikka, Shuchi Mehra, Kausalya Raghuraman, Uma Chaudhary

Abstract


Introduction: Infections due to Gram-negative bacilli are on rise world over. The rampant use of broad-spectrum antibiotics can lead to colonization with resistant strains with an increase in morbidity, mortality, and significant economic loss. Multidrug-resistant organisms (MDRO) by virtue of production of various β-lactamases confer resistance to many classes of antibiotics, particularly cephalosporins.

Material and methods: The present study was conducted over a period of one year on a total of 100 non repetitive MDR isolates of Gram-negative bacilli of family Enterobacteriaceae. All isolates were identified by standard microbiological techniques and antimicrobial susceptibility pattern was determined. American Type Collection (ATCC) strain viz. E. coli. ATCC 25922 was employed as a control strain.Isolates showing reduced susceptibility to third generation cephalosporins were tested for ESBL production as per CLSI guidelines. Isolates showing reduced susceptibility to cefoxitin were screened by AmpC disc test.Isolates showing reduced susceptibility to carbapenems were tested for MBL production by ceftazidime-EDTA disc test.

Results: The prevalence of ESBL, AmpC and MBL was 70%, 39% and 45% respectively. ESBL production along with MBL production was seen in 19% of the  isolates. ESBL production along with AmpC production was seen in 12% of the isolates. MBL production along with AmpC production was observed in 10% of the isolates. Coproduction of all three β-lactamases was observed in 9% of the isolates.

Conclusion: The high prevalence of beta-lactamases emphasizes the need for an early detection  by simple screening methods, which can help in providing an appropriate antimicrobial therapy and in avoiding the development and the dissemination of these multidrug resistant strains.


Keywords


MDRO, ESBL, AmpC, MBL

Full Text:

PDF

References


Livermore DM. Bacterial resistance:origins, epidemiology, and impact. Clin

Infect Dis. 2003;36: S11-23.

Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14:933-51.

Thompson KS. Controversies about Extended-Spectrum and AmpC Beta-lactamases. Emerg Infect Dis. 2001;7:333-6.

Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940;146;146:837.

Handa D, Pandey A, Asthana AK, Rawat A, Handa S, Thakuria B. Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coli. Indian J Pathol Microbiol. 2013;56:135-8.

Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo beta-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005;18:306-25.

Queenan AM, Bush K. Carbapenemases:the versatile β-lactamases. Clin Microbiol Rev.2007;20:440–58.

Poirel L, Dortet L, Bernabeu S, Nordmann P. Genetic features of blaNDM-1 positive Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55:5403-7.

Oberoi L, Singh N, Sharma P, Aggarwal A. ESBL, MBL and AmpC beta-lactamases producing superbugs-Havoc in the Intensive Care Units of Punjab. India J Clin Diagn Res. 2013;7(1):70-3.

Pitout JD, Reisbig MD, Venter EC, Church DL, Hanson ND. Modification of the double disc test for the detection of the Enterobacteriaceae which produced the extended spectrum and the AmpC β lactamases. J Clin microbiol.2003;41:3933-5.

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility test. Twenty first international supplement. CLSI document. M100-S21. Wayne PA;2011.

Magiorakos AP, Srinivasan A, Carey RB, Struelens MJ, Weber JT, Monnet DL et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standards definition for acquired resistance.Clin Microbiol Infect. 2012;18(3): 268-81.

Singhal S, Mathur T, Khan S, Upadhyay DJ, Chugh S, Gaind R, et al. Evaluation of methods for AmpC β-lactamases in Gram-negative clinical isolates from tertiary care hospitals. Indian J Med Microbiol. 2005;23:120-24.

Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antbiotic era? Int J Antimicrob Agents.2007;29:630-6.

Deshmukh DG, Damle AS, Bajaj JK, Bhakre JB. The metallo β lactamase producing clinical isolates from the patients of a tertiary care hospital. Journal of Laboratory Physicians.2011;3(2):93-7.

Kolhapure RM, Kumar A, Rajkumar HR. Co-expression of ESBL, AmpC and MBL in Gram-negative bacilli. Int J Res Med Sci. 2015;3(10):2698-703.

Nagdeo NV, Kaore NM, Thombare VR. Phenotypic methods for detection of various beta-lactamases in Gram negative clinical isolates: Need of the hour. Chron Young Sci. 2012;3:292-8.

Siddiqui N, Bhakre J, Ajit Damle, Bajaj J. Prevalence of Extended Spectrum Beta Lactamase (ESBL) Producing Gram Negative Bacilli from various clinical isolates. IOSR Journal of Dental and Medical Sciences. 2014;13(9): 8-11.

Mathur P, Kapil A, Das B, Dhawan B. The prevalence of ESBL producing gram negative bacteria in a tertiary care hospital. Ind J Med Res. 2002;115:153-7.

Nurul MA, Loo HKC, Subramaniam G, Wong EH, Selvi P, Ho S et al. Faecal prevalence of extended-spectrum β- lactamase (ESBL)-producing coliforms in a geriatric population and among haematology patients. Malaysian J Pathol. 2005;27(2):75-81.

Nevine S. Fam, M M. El-Damarawy. CTX-M-15 Extended-Spectrum Beta-Lactamases Detected from Intensive Care Unit of an Egyptian Medical Research Institute. Research Journal of Medicine and Medical Sciences. 2008;3(1):84-91.

Ali A M, Rafi S, Qureshi AH. Frequency of Extended Spectrum Beta Lactamase Producing Gram Negative Bacilli among Clinical Isolates at Clinical Laboratories of Army Medical College, Rawalpindi. J Ayub Med Coll Abbottabad 2004;16(1):35-7

Mohamudha PR, Harish BN, Parija SC. AmpC Beta lactamases among gram negative clinical isolates from a tertiary hospital, South India. Brazilian J Microbiol. 2010;41:596-602.

Rawat V, Singhai M, Verma PK. Extended-spectrum-beta-lactamase, AmpC, and Carbapenamase issues. J Clin Microbiol 2010;48:1019-25.

Haider M, Rizvi M, Fatima N, Shukla I, Malik A. Necessity of detection of extended spectrum betalactamase, AmpC and metallo-beta-lactamases in Gram negative bacteria isolated from clinical specimens. Muller J Med Sci Res. 2014;5:23-8.

Franklin C, Liolios L, and Peleg AY. Phenotypic detection of carbapenem-susceptible metallo-beta-lactamase-producing gram-negative bacilli in the clinical laboratory. J Clin Microbiol. 2006;44:3139–44.

Jain P, Gandhi V, Patel K, Modi G, Parmar R, Soni S et al. Phenotypic Detection of Metallo-β-lactamase Producing Enterobacteriaceae. International Journal of Microbiology Research. 2012;9:326-9.

Devi A, Ramachander R. Detection of ESBL, Amp C and Metallo Beta Lactamases in Clinical Isolates of Enterobacteriacae from a Tertiary Care Hospital Emergence of Carbapenamase and Other Beta Lactamases among Enterobacteriacae from a Tertiary Care Hospital. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2015;6(5):1377-83.


Refbacks

  • There are currently no refbacks.